Investing.com - MoonLake Immunotherapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
MoonLake Immunotherapeutics announced earnings per share of $-0.27 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.32 on revenue of $0.00.
MoonLake Immunotherapeutics shares are down 67% from the beginning of the year , still down 40.49% from its 52 week high of $15.19 set on Tuesday, April 5, 2022.
MoonLake Immunotherapeutics shares gained 0.89% in intra-day trade the report.
MoonLake Immunotherapeutics follows other major Healthcare sector earnings this month
MoonLake Immunotherapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar